Laser Ablation of Papillary Thyroid Microcarcinoma
Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma
Sponsor: Memorial Sloan Kettering Cancer Center
This PHASE2 trial investigates Papillary Thyroid Microcarcinoma and Thyroid and is currently ongoing. Memorial Sloan Kettering Cancer Center leads this study, which shows 13 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Sep 2022 — Aug 2023 [monthly]
Recruiting PHASE2
-
Mar 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
May 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .